Richard Benjamin - Cerus Chief Medical Officer
| CERS Stock | USD 1.53 0.10 6.99% |
Executive
Dr. Richard J. Benjamin Ph.D., is Chief Medical Officer of the CERUS CORPORATION. Dr. Benjamin was appointed our Chief Medical Officer in July 2015. From January 2006 to June 2015, he served as Chief Medical Officer for the American Red Cross, where he oversaw donor and patient safety issues for approximately 40 percent of the US blood supply. Dr. Benjamin is a Board Member and Regional Director for North America for the International Society of Blood Transfusion, as well as an active member of the American Association of Blood Banks. He has also served on the DHHS Secretarys Advisory Committee on Blood Safety and Availability in the U.S. from since December 2016 and previously served on the committee from 2006 to 2007 since 2015.
| Age | 64 |
| Tenure | 10 years |
| Professional Marks | Ph.D |
| Address | 1220 Concord Avenue, Concord, CA, United States, 94520 |
| Phone | 925 288 6000 |
| Web | https://www.cerus.com |
Richard Benjamin Latest Insider Activity
Tracking and analyzing the buying and selling activities of Richard Benjamin against Cerus stock is an integral part of due diligence when investing in Cerus. Richard Benjamin insider activity provides valuable insight into whether Cerus is net buyers or sellers over its current business cycle. Note, Cerus insiders must abide by specific rules, including filing SEC forms every time they buy or sell Cerus'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Richard Benjamin over a week ago Disposition of 30075 shares by Richard Benjamin of Cerus at 1.45 subject to Rule 16b-3 | ||
Richard Benjamin over two weeks ago Disposition of 261 shares by Richard Benjamin of Cerus at 1.498 subject to Rule 16b-3 | ||
Richard Benjamin over two weeks ago Disposition of 6292 shares by Richard Benjamin of Cerus at 1.5485 subject to Rule 16b-3 | ||
Richard Benjamin over two weeks ago Disposition of 13912 shares by Richard Benjamin of Cerus subject to Rule 16b-3 |
Cerus Management Efficiency
The company has return on total asset (ROA) of (0.0446) % which means that it has lost $0.0446 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3799) %, meaning that it created substantial loss on money invested by shareholders. Cerus' management efficiency ratios could be used to measure how well Cerus manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.11 in 2025. Return On Capital Employed is likely to drop to -0.11 in 2025. At this time, Cerus' Non Current Assets Total are comparatively stable compared to the past year. Non Currrent Assets Other is likely to gain to about 33.6 M in 2025, whereas Total Current Assets are likely to drop slightly above 101.9 M in 2025.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Jens Kemp | Axogen Inc | N/A | |
| Jrme Erath | Pulmonx Corp | N/A | |
| Robert John | CVRx Inc | N/A | |
| Teryl Sides | SurModics | 55 | |
| Michael Wysocki | Rapid Micro Biosystems | N/A | |
| Gordon JD | SurModics | 61 | |
| Helen Leupold | Bioventus | N/A | |
| Scot JD | Treace Medical Concepts | 49 | |
| Jennifer Englund | CVRx Inc | N/A | |
| Daniel Cher | Si Bone | 60 | |
| Frank Vizesi | Orthofix Medical | N/A | |
| Isabelle Billet | Axogen Inc | 62 | |
| CPA CFA | MaxCyte | 56 | |
| Craig Swandal | Axogen Inc | 64 | |
| Manohar Raheja | Sight Sciences | 66 | |
| Stephanie Walsh | Orthofix Medical | N/A | |
| Sean Scanlan | Treace Medical Concepts | 42 | |
| Rosalyn dIncelli | Establishment Labs Holdings | N/A | |
| Paul Pignato | CVRx Inc | N/A | |
| Tonya SPHR | CVRx Inc | 52 | |
| Michael Donovan | Axogen Inc | 59 | |
Management Performance
| Return On Equity | -0.38 | ||||
| Return On Asset | -0.0446 |
Cerus Leadership Team
Elected by the shareholders, the Cerus' board of directors comprises two types of representatives: Cerus inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cerus. The board's role is to monitor Cerus' management team and ensure that shareholders' interests are well served. Cerus' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cerus' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Matthew Notarianni, Director Relations | ||
| Richard Benjamin, Chief Medical Officer | ||
| Kevin Green, CFO and VP of Fin. | ||
| William Greenman, CEO and President and Director | ||
| Carol Moore, Sr. VP of Regulatory Affairs, Quality and Clinical | ||
| Lainie Corten, Sr. Director, Global Marketing & Investor Relations | ||
| Vivek Jayaraman, Chief Commercial Officer | ||
| Chrystal Jensen, Chief Counsel | ||
| Laurence MD, CoFounder Officer | ||
| Jessica Hanover, Vice Affairs | ||
| Chrystal Menard, Chief Legal Officer | ||
| Lori Roll, VP Secretary | ||
| Kevin CPA, VP CFO | ||
| Dr MBChB, Chief Officer | ||
| Laurence Corash, Senior Vice President Chief Medical and Chief Scientific Officer, Director | ||
| Alicia Goodman, Chief Officer | ||
| Chrystal JD, Chief Counsel | ||
| Nina Mufti, Senior Development |
Cerus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cerus a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.38 | ||||
| Return On Asset | -0.0446 | ||||
| Profit Margin | (0.12) % | ||||
| Operating Margin | (0.03) % | ||||
| Current Valuation | 300.97 M | ||||
| Shares Outstanding | 185.79 M | ||||
| Shares Owned By Insiders | 3.25 % | ||||
| Shares Owned By Institutions | 76.30 % | ||||
| Number Of Shares Shorted | 9.31 M | ||||
| Price To Earning | (4.70) X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Cerus Stock Analysis
When running Cerus' price analysis, check to measure Cerus' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cerus is operating at the current time. Most of Cerus' value examination focuses on studying past and present price action to predict the probability of Cerus' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cerus' price. Additionally, you may evaluate how the addition of Cerus to your portfolios can decrease your overall portfolio volatility.